Total
0
Shares
Imagion Biosystems (ASX:IBX) - CEO & President, Bob Proulx - The Market Herald
CEO & President, Bob Proulx
Source: HotCopper
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Imagion Biosystems (IBX) shares are trading in the green as the company enrols the first patient for its MagSense breast cancer phase one study
  • The study will include 15 patients in a bid to test IBX's MagSense nanoparticle technology and its ability as an imaging agent in aiding the staging of HER2 positive breast cancer
  • Broadly, the endpoint of the study is to determine the safety and tolerability of the MagSense imaging agent as well as exploring the effectiveness of the nanoparticles for in vivo detection
  • While current standards of care typically require a biopsy or surgical removal of lymph nodes, Imagion instead affirms their technology detects if a tumour has spread via said imaging agent
  • Imagion Biotech shares are up 38.3 per cent, trading at 13 cents

Imagion Biosystems (IBX) shares are trading in the green as the company enrols the first patient for its MagSense breast cancer phase one study.

The study is expected to enrol 15 patients and marks the first clinical investigation of Imagion Biosystems’ MagSense nanoparticle technology and its ability as an imaging agent in aiding the staging of HER2 positive breast cancer.

Broadly, the endpoint of the study is to determine the safety and tolerability of the MagSense imaging agent as well as exploring the effectiveness of the
nanoparticles for in vivo detection.

According to IBX, MagSense technology detects if the patient's tumour has spread to lymph nodes. Current standards of care typically requiring a biopsy or surgical removal of lymph nodes to confirm metastases - the development of secondary malignant cancer growths.

Imagion Biosystems Executive Chairman Bob Proulx said the team was pleased to report its first patient had been enrolled.

"Though recruiting newly diagnosed cancer patients into a research study can be challenging, we and our investigators remain confident we will reach our recruitment target," he said.

Each patient in the study is set to receive an injection of the MagSense nanoparticle imaging agent and undergoes imaging by MRI while a sample of the lymph node is also assessed.

Imagion Biotech shares are up 38.3 per cent, trading at 13 cents at 1:40 pm AEST.

IBX by the numbers
More From The Market Herald
Adherium (ASX:ADR) - CEO, Rick Legleiter - The Market Herald

" Adherium (ASX:ADR) nabs supply contract for AstraZeneca study in US

Adherium (ADR) has been awarded a supply contract for an upcoming clinical study by AstraZeneca in the United States.
Dimerix (ASX:DXB) - MD and CEO, Dr Nina Webster - The Market Herald

" Dimerix’s (ASX:DXB) DMX-200 closer to COVID-19 study in India

The Indian regulatory agency has recommended that Dimerix’s (DXB) DMX-200 clinical study in COVID-19 patients be approved.
Antisense Therapeutics (ASX:ANP) - MD and CEO - The Market Herald

" Antisense Therapeutics (ASX:ANP) presents new data, files Australian patent

Antisense Therapeutics (ANP) has presented new data to support its ATL1102 drug and also filed another patent in Australia.
Sigman (ASX:SIG) - CEO and Managing Director, Vikesh Ramsunder - The Market Herald

" Sigma Healthcare (ASX:SIG) appoints new CEO

Sigma Healthcare (SIG) has appointed a new Managing Director and CEO to lead the company.